Sanofi Morocco Clarifies: Chloroquine Stock for Domestic Use Only, Not for Export

In a press release, the laboratory explains that Nivaquine (Chloroquine sulfate), indicated in the curative and preventive treatment of malaria, has a marketing authorization "valid only for the Moroccan market". According to Sanofi Morocco, Nivaquine is produced at its industrial site and is not the subject of any export activity.

Furthermore, the laboratory specifies that after receiving the request from the Ministry of Health, it has delivered the entire stock of Nivaquine and also of Plaquenil, indicated in the treatment of rheumatoid arthritis and collagen diseases.

Sanofi Morocco also states that it is closely monitoring, in collaboration with the Ministry of Health, the evolution of clinical trials concerning the chloroquine sulfate molecule and that of hydroxychloroquine.